Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. 2010

Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
Departamento de Farmacologia y Terapeutica, Facultad de Medicina, Instituto Teofilo Hernando, Universidad Autonoma de Madrid, C/Arzobispo Morcillo 4, 28029 Madrid, Spain. cristobal.delosrios@uam.es

1,8-Naphthyridine derivatives related to 17 (ITH4012), a neuroprotective compound reported by our research group, have been synthesized. In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than most tacrine derivatives previously synthesized in our laboratory. The compounds presented an interesting neuroprotective profile in SH-SY5Y neuroblastoma cells stressed with rotenone/oligomycin A. Moreover, compound 14 (ethyl 5-amino-2-methyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate) also caused protection in cells stressed with okadaic acid (OA) or amyloid beta 1-42 peptide (Abeta(1-42)). Interestingly, compound 14 prevented the OA-induced PP2A inhibition, one of the enzymes implicated in tau dephosphorylation. This compound also exhibited neuroprotection against neurotoxicity elicited by oxygen and glucose deprivation in hippocampal slices. Because these stressors caused neuronal damage related to physiopathological hallmarks found in the brain of Alzheimer's disease (AD) patients, we conclude that compound 14 deserves further in vivo studies in AD models to test its therapeutic potential in this disease.

UI MeSH Term Description Entries
D007536 Isomerism The phenomenon whereby certain chemical compounds have structures that are different although the compounds possess the same elemental composition. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Isomerisms
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D009840 Oligomycins A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X). Oligomycin
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors

Related Publications

Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
December 2017, Acta chimica Slovenica,
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
January 2000, Farmaco (Societa chimica italiana : 1989),
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
June 2002, Biological & pharmaceutical bulletin,
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
December 1998, Farmaco (Societa chimica italiana : 1989),
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
January 2001, European journal of medicinal chemistry,
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
March 1976, Il Farmaco; edizione scientifica,
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
January 2002, Anticancer research,
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
January 2015, ACS combinatorial science,
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
October 2009, Journal of enzyme inhibition and medicinal chemistry,
Cristóbal de Los Ríos, and Javier Egea, and José Marco-Contelles, and Rafael León, and Abdelouahid Samadi, and Isabel Iriepa, and Ignacio Moraleda, and Enrique Gálvez, and Antonio G García, and Manuela G López, and Mercedes Villarroya, and Alejandro Romero
August 2002, Farmaco (Societa chimica italiana : 1989),
Copied contents to your clipboard!